Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Transcept Pharmaceuticals, Inc.
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
November 9th, 2008
Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced that a Phase 3 study evaluating the safety and efficacy of its lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), has been published in the September 2008 issue of SLEEP, a publication of the Associated Professional Sleep Societies. Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid to be indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. On September 30, 2008, Transcept submitted a New Drug...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
